Characterizing genomic signatures in predicting renal cell carcinoma therapy response
Light blue digital illustration of DNA strand

Characterizing genomic signatures in predicting renal cell carcinoma therapy response

Project Title: Characterizing genomic signatures in predicting renal cell carcinoma therapy response

Project Duration: 2022-2025

MOHCCN Consortium: Prairie Cancer Consortium

Investigators: Dr. Tarek Bismar and Dr. Daniel Heng

Partners: 

  • University of Calgary

Aim/goals:

To characterize genomic backgrounds of responders’ vs non-responders to current immunotherapies for renal cell carcinoma

 

Summary:

Immunotherapy is the main stay of treatment for renal cell carcinoma. However, to date, clinicians cannot predict which patients may respond or be refractory to treatment. The aim of this project is to characterize genomic backgrounds and biomarkers that could infer response vs resistant to such therapies